CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

May 29-June 2, 2015; Chicago, Illinois
Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 657 KB
Released: May 31, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options, experts provide insights on second-line systemic therapy for advanced HCC.

person default James M. Cleary, MD, PhD Released: January 23, 2020

In this slideset from Clinical Care Options, experts provide insights on the use of immunotherapy for advanced HCC.

Andrew X. Zhu, MD, PhD, FACP Released: January 23, 2020

CME-certified Webcast of a CCO symposium at SITC 2019 featuring expert perspectives on optimal integration of immunotherapy into care of patients with bladder cancer

Elizabeth R. Plimack, MD, MS
Program Director
Matthew Galsky, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2020 Expiration: January 22, 2021

In this slideset from Clinical Care Options, experts provide insights on the use of first-line systemic therapy for advanced HCC.

Stacey Stein, MD Released: January 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?